{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:24:11Z","timestamp":1783056251019,"version":"3.54.6"},"reference-count":35,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2021,5,27]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Our knowledge about the effect of tocilizumab (TCZ) on the synovium in rheumatoid arthritis (RA) is limited. The aim of this study was to investigate the effect of TCZ on citrullination and on inflammation in the synovial tissue and in the peripheral blood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>15 patients with RA underwent synovial biopsy before and 8 weeks after TCZ initiation. Clinical evaluation was performed at baseline and at 8 weeks. Using immunohistochemistry, we evaluated the expression of CD68, CD3, CD20, osteoprotegerin (OPG) and receptor activator for nuclear factor-\u03baB ligand (RANKL) before and after treatment with TCZ. We also analysed the expression of protein arginine deiminase (PAD)-2 and PAD-4 enzymes in the synovial tissue and protein citrullination patterns with the help of anticitrullinated protein antibody (ACPA) clones 1325:04C03 and 1325:01B09. Serum levels of interleukin-6 (IL-6), IL-8, RANKL, OPG and C-terminal crosslinked telopeptide type II collagen were measured by ELISA. Paired-wise Wilcoxon signed-rank test was used to compare median values before and after treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Disease activity in patients was reduced from baseline to 8 weeks. Although PAD-2 and PAD-4 expressions remained unchanged after TCZ treatment, the binding of one ACPA clone decreased in the synovial tissue. TCZ did not affect the number of CD68+ macrophages\u2009or CD20+ B cells but induced significant decrease in the number of CD3+ T cells. RANKL and OPG expression remained unchanged in the synovial tissue. A significant increase in the levels of IL-6 and RANKL was observed in the serum. This increase was statistically significant in patients who responded to TCZ (achieving Clinical Disease Activity Index low disease activity or remission) but not in non-responders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>TCZ reduced synovial T-cell counts but not macrophages. A significant increase of serum IL-6 was observed in responders.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-001662","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T13:14:19Z","timestamp":1623330859000},"page":"e001662","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2669-1247","authenticated-orcid":false,"given":"Katerina","family":"Chatzidionysiou","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Gastroentorogy, Dematology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Circiumaru","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden"},{"name":"Centrum for Rheumatology, Academic Specialist Centrum, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8220-5015","authenticated-orcid":false,"given":"Bence","family":"Rethi","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-8180","authenticated-orcid":false,"given":"Vijay","family":"Joshua","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Engstrom","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aase","family":"Hensvold","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden"},{"name":"Centrum for Rheumatology, Academic Specialist Centrum, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"af Klint","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Gastroentorogy, Dematology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1292-1152","authenticated-orcid":false,"given":"Anca","family":"Catrina","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Gastroentorogy, Dematology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"2025090312502876000_7.2.e001662.1","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0338"},{"key":"2025090312502876000_7.2.e001662.2","doi-asserted-by":"crossref","DOI":"10.1186\/ar1917","article-title":"Interleukin-6 and chronic inflammation","volume":"8 Suppl 2","author":"Gabay","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2025090312502876000_7.2.e001662.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2004.12.013"},{"key":"2025090312502876000_7.2.e001662.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.153"},{"key":"2025090312502876000_7.2.e001662.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.22033"},{"key":"2025090312502876000_7.2.e001662.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"2025090312502876000_7.2.e001662.7","doi-asserted-by":"crossref","unstructured":"Genovese MC , McKay JD , Nasonov EL . Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug the. Arthritis Rheum 2008.","DOI":"10.1002\/art.23940"},{"key":"2025090312502876000_7.2.e001662.8","doi-asserted-by":"crossref","unstructured":"Burmester GR , Rubbert-Roth A , Cantagrel A . A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid art. Ann Rheum Dis 2014.","DOI":"10.1136\/annrheumdis-2013-203523"},{"key":"2025090312502876000_7.2.e001662.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.20664"},{"key":"2025090312502876000_7.2.e001662.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.5.502"},{"key":"2025090312502876000_7.2.e001662.11","doi-asserted-by":"crossref","unstructured":"Smeets TJM , Kraan MC , Van Loon ME . Tumor necrosis factor \u03b1 blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003.","DOI":"10.1002\/art.11098"},{"key":"2025090312502876000_7.2.e001662.12","unstructured":"Makrygiannakis D , Revu S , Neregard P . Glucocorticoids decrease the expression of synovial citrullinated proteins in rheumatoid arthritis. Arthritis Rheum 2009."},{"key":"2025090312502876000_7.2.e001662.13","doi-asserted-by":"crossref","unstructured":"Arnett FC , Edworthy SM , Bloch DA . The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988.","DOI":"10.1002\/art.1780310302"},{"key":"2025090312502876000_7.2.e001662.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204603"},{"key":"2025090312502876000_7.2.e001662.15","doi-asserted-by":"crossref","unstructured":"Steen J , Forsstr\u00f6m B , Sahlstr\u00f6m P . Recognition of amino acid motifs, rather than specific proteins, by human plasma Cell\u2013Derived monoclonal antibodies to posttranslationally modified proteins in rheumatoid arthritis. Arthritis Rheumatol 2019.","DOI":"10.1002\/art.40699"},{"key":"2025090312502876000_7.2.e001662.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2006.02508.x"},{"key":"2025090312502876000_7.2.e001662.17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.38202","article-title":"Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium","volume":"66","author":"Ducreux","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090312502876000_7.2.e001662.18","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830180427"},{"key":"2025090312502876000_7.2.e001662.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090348"},{"key":"2025090312502876000_7.2.e001662.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029751"},{"key":"2025090312502876000_7.2.e001662.21","doi-asserted-by":"crossref","unstructured":"Tak PP , Smeets TJM , Daha MR . Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997.","DOI":"10.1002\/art.1780400206"},{"key":"2025090312502876000_7.2.e001662.22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000527"},{"key":"2025090312502876000_7.2.e001662.23","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat Med"},{"key":"2025090312502876000_7.2.e001662.24","doi-asserted-by":"crossref","unstructured":"Tak PP , Taylor PC , Breedveld FC . Decrease in cellularity and expression of adhesion molecules by anti- tumor necrosis factor \u03b1 monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996.","DOI":"10.1002\/art.1780390702"},{"key":"2025090312502876000_7.2.e001662.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208093"},{"key":"2025090312502876000_7.2.e001662.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214967"},{"key":"2025090312502876000_7.2.e001662.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-155846"},{"key":"2025090312502876000_7.2.e001662.28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121389"},{"key":"2025090312502876000_7.2.e001662.29","doi-asserted-by":"crossref","unstructured":"Hensvold AH , Joshua V , Li W , et al . Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate. Arthritis Res Ther 2015;17.doi:10.1186\/s13075-015-0760-9","DOI":"10.1186\/s13075-015-0760-9"},{"key":"2025090312502876000_7.2.e001662.30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.6.3353"},{"key":"2025090312502876000_7.2.e001662.31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.24.11924"},{"key":"2025090312502876000_7.2.e001662.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.24781"},{"key":"2025090312502876000_7.2.e001662.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200395"},{"key":"2025090312502876000_7.2.e001662.34","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835fd8eb"},{"key":"2025090312502876000_7.2.e001662.35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate Responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-001662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:50:34Z","timestamp":1756929034000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6,10]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/rmdopen-2021-001662"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001662","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}